Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to "Buy" at StockNews.com

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) was upgraded by research analysts at StockNews.com from a "hold" rating to a "buy" rating in a note issued to investors on Thursday.

A number of other equities analysts also recently issued reports on the stock. Needham & Company LLC reissued a "buy" rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 9th. Citigroup increased their target price on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. Royal Bank of Canada lifted their price target on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a research report on Friday, March 21st. Stifel Nicolaus increased their price objective on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a report on Monday, March 31st. Finally, Canaccord Genuity Group boosted their target price on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have assigned a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $319.17.

Alnylam Pharmaceuticals Trading Up 2.5 %

NASDAQ ALNY opened at $276.55 on Thursday. The stock has a market cap of $35.98 billion, a P/E ratio of -127.44 and a beta of 0.17. Alnylam Pharmaceuticals has a fifty-two week low of $144.73 and a fifty-two week high of $304.39. The stock has a 50 day simple moving average of $250.06 and a two-hundred day simple moving average of $254.80. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. The firm's revenue for the quarter was up 20.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.16) earnings per share. On average, analysts forecast that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the sale, the chief executive officer now directly owns 81,526 shares of the company's stock, valued at approximately $20,802,989.42. This represents a 1.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the transaction, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. This represents a 10.06 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 7,392 shares of company stock worth $1,875,627. Company insiders own 1.50% of the company's stock.

Institutional Trading of Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Nordea Investment Management AB raised its holdings in Alnylam Pharmaceuticals by 6.7% during the fourth quarter. Nordea Investment Management AB now owns 10,188 shares of the biopharmaceutical company's stock valued at $2,417,000 after acquiring an additional 637 shares during the period. Fulton Bank N.A. raised its stake in Alnylam Pharmaceuticals by 28.9% during the 4th quarter. Fulton Bank N.A. now owns 1,343 shares of the biopharmaceutical company's stock valued at $316,000 after purchasing an additional 301 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in Alnylam Pharmaceuticals by 0.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 6,512 shares of the biopharmaceutical company's stock worth $1,532,000 after purchasing an additional 58 shares in the last quarter. Harbor Capital Advisors Inc. boosted its stake in Alnylam Pharmaceuticals by 2.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 2,650 shares of the biopharmaceutical company's stock worth $624,000 after purchasing an additional 63 shares during the period. Finally, Pallas Capital Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 2.6% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,408 shares of the biopharmaceutical company's stock valued at $802,000 after buying an additional 87 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.